ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.97 CNY | +0.40% |
|
+2.05% | -2.45% |
| Apr. 25 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.45% | 2.29B | D+ | ||
| -4.06% | 86.13B | A- | ||
| +1.97% | 39.82B | A- | ||
| +56.59% | 25.23B | A | ||
| -14.82% | 15.36B | C | ||
| -8.82% | 11.95B | D+ | ||
| -16.29% | 11.6B | B- | ||
| -41.58% | 11.51B | B | ||
| +6.14% | 8.71B | B+ | ||
| -7.02% | 8.12B | B- |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300009 Stock
- Ratings Anhui Anke Biotechnology (Group) Co., Ltd.
